|  The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic: - In a March 22 Consumer Update, the FDA provided an update on simple steps to help slow the spread of coronavirus disease to protect ourselves, our families and our communities. Read more: Help Stop the Spread of Coronavirus and Protect Your Family.
- The FDA and the NIH CURE ID app has received the 2021 Golan Christie Taglia Patient Impact Philanthropy Award from Cures Within Reach. CURE ID is an internet-based repository that lets the clinical community share novel uses of existing drugs for difficult-to-treat infectious diseases. The FDA and the NIH have made critical updates to CURE ID to be a more effective tool during COVID-19.
- As part of the FDA's effort to protect consumers, the agency issued a warning letter jointly with the Federal Trade Commission to PYRLess Group, LLC dba Dr. Fitt for selling unapproved products with fraudulent COVID-19 claims. The FDA requested that the company take immediate action to cease the sale of any unapproved and misbranded products for the treatment or prevention of COVID-19. Consumers concerned about COVID-19 should consult with their health care providers.
- Testing updates:
- As of today, 343 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 255 molecular tests and sample collection devices, 73 antibody and other immune response tests, and 15 antigen tests. There are 41 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, two antigen prescription at-home tests, one over-the-counter (OTC) at-home antigen test, and one OTC molecular test.
| | | |
No comments:
Post a Comment